Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
450
Combination of Fenofibrate and Simvastatin 40mg
Simvastatin 40mg
Triglycerides
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Time frame: 12 weeks
Percent change from baseline to 24 weeks of treatment in Triglycerides
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in HDL-C
Time frame: 24 weeks
Percent change from baseline to 24 weeks of treatment in LDL-C
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site 204
Adelaide, Australia
Site 214
Adelaide, Australia
Site 203
Bendigo, Australia
Site 207
Brisbane, Australia
Site 208
Brisbane, Australia
Site 221
Brisbane, Australia
Site 202
Burnie, Australia
Site 201
Camperdown, Australia
Site 220
Coffs Harbour, Australia
Site 218
Daw Park, Australia
...and 57 more locations